EHA 2025 | Interim results from a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL

We’re very excited to share interim results of this study, looking at epcoritamab, a bispecific antibody targeting CD3 and CD20 in combination with lenalidomide, an immunomodulatory agent, in frontline follicular. And we have at this time 18 patients enrolled between January of 2023 and February 2025. And out of these 18 patients, 12 patients are response evaluable. Patients get this time-limited treatment for 12 cycles for a total of a year. And in the patients treated so far, we’ve actually observed very good safety and toxicity and tolerability. We’ve had no fatal events, no febrile neutropenia or treatment-related infections. Cytokine release syndrome was observed in 10 patients, any grade and one patient grade three. And otherwise common side effects included cytopenias, rash, fatigue, injection site reaction, dry skin, among others, but overall very well tolerable. In terms of response rates, fantastic, 100% overall response rate with a 92% CR rate and an 8% PR rate. And in the median follow-up of 9.2 months, all of the 12 patients who are response evaluable have achieved a response and continue to have ongoing response. So I think we’re very excited by these interim results of the study, and we’re looking forward to finishing up accrual relatively soon and sharing the full final results of the study.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.